No Data
No Data
PainReform Announces Crucial Shareholders Meeting
Maxim Group Maintains PainReform(PRFX.US) With Buy Rating, Maintains Target Price $2
Maxim Group analyst Naz Rahman maintains $PainReform(PRFX.US)$ with a buy rating, and maintains the target price at $2.According to TipRanks data, the analyst has a success rate of 26.8% and a total a
Express News | On June 24, PainReform Ilan Hadar, CEO & CFO Ceased His Service To Co; Appointed Ehud Geller As Interim CEO & CFO
Express News | PainReform Ltd: Appointed Ehud Geller as Interim CEO & CFO
Express News | PainReform Ltd: On June 24, Ilan Hadar, CEO & CFO Ceased His Service to Co
Express News | Maxim Group Reiterates Buy on PainReform, Maintains $2 Price Target
No Data